

New Compound that Stimulates Immune Cells to Eliminate Cancers

Tech ID: 22177 / UC Case 2011-202-0

GENERAL INFORMATION

Cytokines, such as interferon-alpha and interleukin-2, have been used to treat cancer patients with limited success. Unfortunately, these cytokines also have profound side effects that limit their use. A UC San Diego researcher has developed a novel method to treat and prevent cancer using the cytokine IL-17D which stimulates immune cells to eliminate cancers. Such an approach does not cause side effects seen with other pro-inflammatory members of the IL-17 family.

Efficacy of this new method has been shown in mouse models; initially with overexpression of IL-17D in implanted tumor lines, but more recently using exogenously applied IL-17D as would occur in clinical use. Although a full publication on this material is still pending, two abstracts may be reviewed at:

[IL-17D mediated cancer rejection](#)

[Timothy O'Sullivan, Robert Saddawi-Konefka, and Jack Bui](#)

[IL-17D, natural killer cells, and macrophages collaborate to promote tumor rejection \(P2097\) Jack Bui, Timothy O'Sullivan, Robert Saddawi-Konefka, and Emilie Gross](#)

Detailed description of technology is available under secrecy agreement.

PATENT STATUS

Country	Type	Number	Dated	Case
United States Of America	Issued Patent	9,205,131	12/08/2015	2011-202

CONTACT

University of California, San Diego
Office of Innovation and Commercialization
innovation@ucsd.edu
tel: 858.534.5815.



INVENTORS

► [Bui, Jack D.](#)

OTHER INFORMATION

CATEGORIZED AS

- [Medical](#)
- [Disease: Cancer](#)

RELATED CASES

[2011-202-0](#)